[{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Healiva","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Tissue-engineered Autologous Outer Root Sheath Keratinocytes","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"B. Braun Medical \/ Healiva","highestDevelopmentStatusID":"12","companyTruncated":"B. Braun Medical \/ Healiva"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"B. Braun Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"B. Braun Medical \/ Not Applicable"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Cefazolin Sodium","moa":"||Bacterial Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"B. Braun Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"B. Braun Medical \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by B. Braun Medical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : Cefazolin sodium is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. It is indicated for several infections, like respiratory, urinary infections in adult and pediatric.

                          Product Name : Cefazolin Sodium Injection

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          March 24, 2025

                          Lead Product(s) : Cefazolin Sodium,Dextrose

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : Levetiracetam is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.

                          Product Name : Levetiracetam-Generic

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 28, 2024

                          Lead Product(s) : Levetiracetam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis derived from the patient’s own hair cells.

                          Product Name : Epidex

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 21, 2022

                          Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocytes

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Approved

                          Sponsor : Healiva

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank